Related Experiment Video
Updated: Aug 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Successful use of recombinant factor VIIa in pelvic fracture haemorrhage
Kumar K Dhruva1, V D Joel, S Antony
1Medical Trust Hospital, Cochin, Kerala 682016.
Recombinant factor VIIa is a novel haemostatic agent and was originally developed to treat haemophilia patients. Successful use of the factor in a 30-year-old male patient with pelvic fracture haemorrhage is being described by the authors.
Recombinant factor VIIa is a novel haemostatic agent and was originally developed to treat haemophilia patients. Successful use of the factor in a 30-year-old male patient with pelvic fracture haemorrhage is being described by the authors.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Clot Retraction and Fibrinolysis